Middle East Pharmaceutical Industries Company SJSC
SAU:4016
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
|
SA |
|
Interspace Co Ltd
TSE:2122
|
JP |
|
S
|
State Bank of India
LSE:SBID
|
IN |
|
Okapi Resources Ltd
ASX:OKR
|
AU |
|
National Company for Learning and Education SJSC
SAU:4291
|
SA |
|
Canature Health Technology Group Co Ltd
SZSE:300272
|
CN |
|
Berentzen Gruppe AG
XETRA:BEZ
|
DE |
|
T
|
Tanco Holdings Bhd
KLSE:TANCO
|
MY |
|
Dafeng TV Ltd
TWSE:6184
|
TW |
|
Grupo Financiero Banorte SAB de CV
BMV:GFNORTEO
|
MX |
Balance Sheet
Balance Sheet Decomposition
Middle East Pharmaceutical Industries Company SJSC
Middle East Pharmaceutical Industries Company SJSC
Balance Sheet
Middle East Pharmaceutical Industries Company SJSC
| Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Cash Equivalents |
16
|
19
|
24
|
15
|
23
|
34
|
|
| Cash |
16
|
19
|
24
|
15
|
23
|
34
|
|
| Total Receivables |
113
|
167
|
157
|
173
|
225
|
261
|
|
| Accounts Receivables |
110
|
164
|
152
|
163
|
217
|
257
|
|
| Other Receivables |
3
|
3
|
6
|
10
|
8
|
4
|
|
| Inventory |
83
|
74
|
100
|
87
|
94
|
104
|
|
| Other Current Assets |
14
|
9
|
10
|
10
|
14
|
14
|
|
| Total Current Assets |
225
|
269
|
291
|
285
|
355
|
413
|
|
| PP&E Net |
95
|
103
|
106
|
119
|
121
|
124
|
|
| PP&E Gross |
95
|
103
|
106
|
119
|
121
|
124
|
|
| Accumulated Depreciation |
53
|
60
|
65
|
73
|
81
|
93
|
|
| Intangible Assets |
28
|
34
|
41
|
47
|
51
|
62
|
|
| Long-Term Investments |
23
|
10
|
4
|
1
|
0
|
0
|
|
| Total Assets |
371
N/A
|
417
+12%
|
442
+6%
|
453
+2%
|
527
+16%
|
600
+14%
|
|
| Liabilities | |||||||
| Accounts Payable |
26
|
33
|
38
|
28
|
27
|
44
|
|
| Accrued Liabilities |
10
|
8
|
10
|
23
|
30
|
33
|
|
| Short-Term Debt |
42
|
66
|
69
|
52
|
62
|
37
|
|
| Current Portion of Long-Term Debt |
0
|
5
|
6
|
6
|
3
|
5
|
|
| Other Current Liabilities |
6
|
6
|
8
|
12
|
11
|
13
|
|
| Total Current Liabilities |
85
|
117
|
132
|
121
|
134
|
132
|
|
| Long-Term Debt |
21
|
16
|
10
|
3
|
0
|
22
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
13
|
17
|
21
|
22
|
25
|
30
|
|
| Total Liabilities |
118
N/A
|
150
+27%
|
162
+8%
|
146
-10%
|
159
+8%
|
183
+16%
|
|
| Equity | |||||||
| Common Stock |
60
|
60
|
200
|
200
|
200
|
200
|
|
| Retained Earnings |
192
|
207
|
80
|
106
|
168
|
216
|
|
| Total Equity |
252
N/A
|
267
+6%
|
280
+5%
|
306
+9%
|
368
+20%
|
416
+13%
|
|
| Total Liabilities & Equity |
371
N/A
|
417
+12%
|
442
+6%
|
453
+2%
|
527
+16%
|
600
+14%
|
|
| Shares Outstanding | |||||||
| Common Shares Outstanding |
20
|
20
|
20
|
20
|
20
|
20
|
|